Currently, small-molecule imaging with gallium- or fluoride-labelled prostate-specific membrane antigen (68Ga/18F-PSMA) has been rapidly taken into clinical use in many European countries [1–3], although its utility in primary staging of prostate cancer still needs further validation [4–6]. The gene discussed is FOLH1; the disease is prostate cancer.